Phase 2 Readout~quarter
Phase 2 Readout: obexelimab
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Drug
- obexelimab
- Indication
- Systemic Lupus Erythematosus
Other upcoming events for ZBIO
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
Phase 2 ReadoutPhase 2 Readout: obexelimab
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.